局部热疗治疗睑板腺功能障碍：疗效的单中心回顾性时间分析。
Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time.
机构信息
Vance Thompson Vision Center, Sioux Falls, South Dakota.
The Ohio State University, Columbus, Ohio.
出版信息
Optom Vis Sci. 2023 Sep 1;100(9):625-630. doi: 10.1097/OPX.0000000000002053. Epub 2023 Aug 12.
SIGNIFICANCE
Meibomian gland dysfunction (MGD) can produce a myriad of symptoms. The effective treatment of MGD can reduce the burden of this condition. Although several studies have indicated that TearCare (Sight Sciences, Menlo Park, CA) is an effective treatment for MGD, no studies currently provide information regarding the duration of efficacy.
PURPOSE
The purpose of this analysis was to determine the duration of efficacy of symptom relief and improvement of signs (as measured by gland function) for a treatment consisting of controlled heating of the meibomian glands using SmartLids (Sight Sciences) combined with manual expression of the liquefied meibum by a physician.
METHODS
This study involved retrospective analysis of data gathered from a single-center ophthalmology/optometry practice. Symptoms were assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and the signs were assessed using the meibomian gland expression (MGE) scores before and at several time points (8 weeks, 6 months, 12 months, and 18 months). Further analysis evaluating the efficacy in subgroups based on age, race, and sex was performed.
RESULTS
There were 78 patients included in this study. The mean baseline SPEED score decreased from 14 to 7.9 at 8 weeks. The mean SPEED scores at 6 and 12 months were maintained at 7.7 and 7.9, respectively, and at 18 months went to 8.9. At baseline, the mean MGE was 4.9 in the right eye and 4.8 in the left eye. In both eyes, the mean MGE increased to 9.0 in both eyes at 8 weeks. At 6 months, the mean MGE score was maintained at 8.6 in the right and 8.2 in the left and remained consistent at 12 months with 7.8 in the right and 7.8 in the left. At 18 months, the MGE score went to 6.8 in the right eye and 7.0 in the left eye.
CONCLUSIONS
A single TearCare treatment effectively reduced both the symptoms and signs of MGD and maintained its effects for 12 months.
意义
睑板腺功能障碍 (MGD) 可产生多种症状。MGD 的有效治疗可以减轻这种疾病的负担。尽管有几项研究表明 TearCare（Sight Sciences，Menlo Park，CA）是治疗 MGD 的有效方法，但目前尚无研究提供有关疗效持续时间的信息。
目的
本分析的目的是确定使用 SmartLids（Sight Sciences）对睑板腺进行受控加热与医生手动液化睑脂相结合的治疗方法在缓解症状和改善体征（通过腺体功能测量）方面的疗效持续时间，体征包括腺体功能评估（MGE）评分。
方法
本研究涉及对单中心眼科/验光实践中收集的数据进行回顾性分析。使用标准患者眼干评估问卷 (SPEED) 评估症状，使用睑板腺分泌评估 (MGE) 评分评估体征，分别在基线和 8 周、6 个月、12 个月和 18 个月时进行评估。还对基于年龄、种族和性别的亚组进行了疗效评估。
结果
本研究共纳入 78 例患者。平均基线 SPEED 评分从 14 分降至 8 周时的 7.9 分。6 个月和 12 个月的平均 SPEED 评分分别维持在 7.7 和 7.9，18 个月时为 8.9。基线时，右眼和左眼的平均 MGE 分别为 4.9 和 4.8。在右眼和左眼，MGE 均在 8 周时增加到 9.0。6 个月时，右眼和左眼的平均 MGE 评分分别维持在 8.6 和 8.2，12 个月时分别为 7.8 和 7.8。18 个月时，右眼和左眼的 MGE 评分分别降至 6.8 和 7.0。
结论
单次 TearCare 治疗可有效减轻 MGD 的症状和体征，并在 12 个月内保持疗效。
Zotero 插件